These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 33252908)

  • 41. Parkinson disease treatment in hospitals and nursing facilities: avoiding pitfalls.
    Ahlskog JE
    Mayo Clin Proc; 2014 Jul; 89(7):997-1003. PubMed ID: 24996235
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Levodopa/carbidopa/entacapone in Parkinson's disease.
    Seeberger LC; Hauser RA
    Expert Rev Neurother; 2009 Jul; 9(7):929-40. PubMed ID: 19589043
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Treatment of Parkinson disease].
    Cardoso F
    Arq Neuropsiquiatr; 1995 Mar; 53(1):1-10. PubMed ID: 7575192
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Parkinson's disease: diagnosis and treatment.
    Rao SS; Hofmann LA; Shakil A
    Am Fam Physician; 2006 Dec; 74(12):2046-54. PubMed ID: 17186710
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Parkinson disease: managing a complex, progressive disease at all stages.
    Giroux ML
    Cleve Clin J Med; 2007 May; 74(5):313-4, 317-8, 320-2 passim. PubMed ID: 17506237
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial).
    Boiko AN; Batysheva TT; Minaeva NG; Babina LA; Vdovichenko TV; Zhuravleva EY; Shikhkerimov RK; Malykhina EA; Khozova AA; Zaitsev KA; Kostenko EV
    Neurosci Behav Physiol; 2008 Nov; 38(9):933-6. PubMed ID: 18975095
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treating the progressive stages of Parkinson's disease.
    Varon J; Jacobs MB
    Postgrad Med; 1991 Jul; 90(1):63-6, 69-71. PubMed ID: 1905807
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Contemporary Options for the Management of Motor Complications in Parkinson's Disease: Updated Clinical Review.
    Cabreira V; Soares-da-Silva P; Massano J
    Drugs; 2019 Apr; 79(6):593-608. PubMed ID: 30905034
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical inquiry. Which drugs work best for early Parkinson's disease?
    Jain L; Benko R; Safranek S
    J Fam Pract; 2012 Feb; 61(2):106-8. PubMed ID: 22312616
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of motor fluctuations in Parkinson's disease: recent developments and future directions.
    Ramirez-Zamora A; Molho E
    Expert Rev Neurother; 2014 Jan; 14(1):93-103. PubMed ID: 24328720
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Levodopa/Carbidopa Enteral Suspension: A Review in Advanced Parkinson's Disease.
    Hoy SM
    Drugs; 2019 Oct; 79(15):1709-1718. PubMed ID: 31549300
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Parkinson Disease: Current and Emerging Treatment Strategies.
    Ramirez-Zamora A
    J Clin Psychiatry; 2018; 79(3):. PubMed ID: 29999254
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Carbidopa levodopa enteral suspension.
    Seeberger LC; Hauser RA
    Expert Opin Pharmacother; 2015; 16(18):2807-17. PubMed ID: 26595228
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Use of advanced therapies for Parkinson's disease in Norway.
    Ezat B; Pihlstrøm L; Aasly J; Tysnes OB; Egge A; Dietrichs E
    Tidsskr Nor Laegeforen; 2017 May; 137(9):619-623. PubMed ID: 28468476
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rationale for continuous dopaminomimetic therapy of Parkinson's disease.
    Chase TN; Baronti F; Fabbrini G; Heuser IJ; Juncos JL; Mouradian MM
    Neurology; 1989 Nov; 39(11 Suppl 2):7-10; discussion 19. PubMed ID: 2685653
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Parkinson's disease. Update in diagnosis and symptom management.
    Marjama-Lyons JM; Koller WC
    Geriatrics; 2001 Aug; 56(8):24-5, 29-30, 33-5. PubMed ID: 11505857
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Two advances in the management of Parkinson disease.
    Montgomery EB
    Cleve Clin J Med; 2002 Aug; 69(8):639-43. PubMed ID: 12184472
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Influence of levodopa, stalevo on dyskinesia in Parkinson's disease: STRIDE-PD study].
    Liashchenko EA; Skripkina NA; Levin OS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(7 Pt 2):62-8. PubMed ID: 23994933
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of subthalamic nucleus deep brain stimulation and Duodopa in the treatment of advanced Parkinson's disease.
    Merola A; Zibetti M; Angrisano S; Rizzi L; Lanotte M; Lopiano L
    Mov Disord; 2011 Mar; 26(4):664-70. PubMed ID: 21469197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.